C
CERT
Certara, Inc.
9.13
+0.49+5.67%After Hours: 9.16 +0.03 +0.33%19:45 10/09 EDT
OPEN/PREV CLOSE8.85/8.64
TODAY RANGE8.64-9.27
VOL5.04M
MARKET CAP1.39B
52 WEEK RANGE4.450-13.69
AVG VOL (3M)3.09M
% TURNOVER2.51%
TURNOVER--
P/E (TTM)-20.6983
% RANGE7.29%
EPS(TTM)-0.4411
P/E(FORWARD)-41.1855
P/B1.441
BVPS6.34
DIVIDEND--
P/S3.469
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.02B
SHARES OUTSTANDING152.54M
NEXT EARNINGS11/02-11/17
FREE FLOAT112.03M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Dow Jones·2d ago
Certara Is Maintained at Equal-Weight by Barclays
TipRanks·3d ago
Certara price target raised to $9 from $7.50 at Barclays
TipRanks·3d ago
Barclays Sticks to Its Hold Rating for Certara (CERT)
Benzinga·09/30 19:17
'HHS launches project to speed up clinical trials' - Axios
Dow Jones·09/30 16:14
Certara Cut to Neutral From Buy by UBS
Dow Jones·09/30 16:14
Certara Price Target Maintained With a $10.00/Share by UBS
Benzinga·09/30 16:05
UBS Downgrades Certara to Neutral, Maintains Price Target to $10
TipRanks·09/30 09:35
Certara resumed with a Neutral at UBS
Simply Wall St·09/16 13:26
Certara Stock Is Up 5.0% What's Changed After Software Growth And Job Cuts
Simply Wall St·09/14 08:12
Certara (CERT) Software Growth Meets Restructuring Costs, Is The Stock Still A Bargain?
Seeking Alpha·08/25 17:53
HHS said to be eyeing two new FDA deputy commissioners for technology and drugs
Simply Wall St·08/11 18:28
How Investors Are Reacting To Certara (CERT) Expanding Buybacks Amid Wider Losses And Leadership Changes
TipRanks·08/07 20:50
Certara Corrects EBITDA Disclosure in Earnings Presentation